Recent trials of allogeneic GM-CSF-secreting tumor cell vaccines in non-melanoma cancers have demonstrated an association of T cell and immunoglobulin responses raised against shared tumor antigens, with favorable clinical outcomes. The gene discussed is CSF2; the disease is cancer.